Please assess the completion status of the following clinical trial:

Trial Title: Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women (\>18 years old, \<65 years old)~* Patients with lower urinary tract symptoms (hesitancy, intermittency decreased force and caliber of urinary stream, urgency, incontinence) and urodynamic finding compatible with diagnosis of DV in multichannel videourodynamics. (Non relaxation or over stimulation of EMG activity, and stress pattern of voiding)~* Established symptoms for at least six months~* Patients with defecatory symptom should have symptoms of constipation (must include 2 or more of the following: straining during 25% of defecations, hard or lumpy stools during 25% of defecation, sensation of incomplete evacuation upon defecations, sensation of anorectal blockage or obstruction during 25% of defecations, manual maneuvers to facilitate 25% of defecations; loose stools that are rarely present without the use of laxatives; insufficient criteria to meet the definition of IBS-C.~Exclusion Criteria:~* Overt neurogenic disease~* Significant bladder outlet obstruction~* Detrusor instability on Urodynamic study~* Detrusor hypo contractility due to neurogenic causes~* Previous pelvic radiation~* Present (and past) malignancy of bladder or prostate~* Present or recurrent UTI (3 or more documented UTI in the past year )~* Interstitial Cystitis~* Diabetic neuropathy~* Patients on anticholinergic medications~* Bladder stones~* Urinary retention~* Underlying dementia or significant cognitive impairment.~* Patients unwilling to undergo videourodynamic , EMG or anorectal manometry testing~* Sample size: 62 patients in total (calculation basis described on Statistical Plan for Data Analysis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Baclofen, Then Placebo (Type: ACTIVE_COMPARATOR): Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
- Placebo, Then Baclofen (Type: PLACEBO_COMPARATOR): Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).